$3.27
+0.34 (+11.60%)
Open$3.02
Previous Close$2.93
Day High$3.27
Day Low$3.00
52W High$14.52
52W Low$7.07
Volume—
Avg Volume785.8K
Market Cap101.49M
P/E Ratio24.93
EPS$0.42
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+295.4% upside
Current
$3.27
$3.27
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.67M | 15.02M | 12.01M |
| Net Income | -500,971 | -500,427 | -503,355 |
| Profit Margin | -3.4% | -3.3% | -4.2% |
| EBITDA | -840,494 | -867,054 | -674,727 |
| Free Cash Flow | -393,962 | -309,659 | -330,972 |
| Rev Growth | +7.4% | +23.3% | -6.8% |
| Debt/Equity | 0.83 | 0.77 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |